Go back to trials list
An Open-Label, Multicenter, Phase 1 Study of IGM-2644 in Participants With Relapsed and/or Refractory Multiple Myeloma
Description
This is a first in human, phase 1, multicenter, open-label study to determine the safety and tolerability of IGM-2644 as a single agent in participants with relapsed and/or refractory MM, for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is considered inappropriate. Dose escalation and dose expansion cohorts will be enrolled to evaluate safety, preliminary efficacy, and further define a RP2D. The total length of the study, from screening of the first participant to the end of the study, is expected to be approximately 60 months.Patients will be enrolled in two stages: a dose-escalation stage and a dose expansion stage. The escalation stage will investigate single agent IGM-2644 safety and tolerability in patients with relapsed and/or refractory multiple myeloma. The dose expansion cohort(s) will further evaluate safety, PK/PD, and preliminary efficacy of the recommended phase 2 dose (RP2D). IGM-2644 will be administered intravenously (IV).
Trial Eligibility
Inclusion Criteria: * Adults \> 18 years at time of consent * ECOG performance status of 0 or 1 * Relapsed and/or refractory multiple myeloma after ≥ 3 prior lines; Must have failed treatment with an IMiD, PI, and anti-CD38 therapy * Measurable disease per the IMWG response criteria * Adequate marrow and organ function without transfusion or growth factor support within 7 days prior to screening * Willing and able to undergo bone marrow aspirate and biopsy per protocol Exclusion Criteria: * Inability to comply with study and follow-up procedures * History of clinically significant primary amyloidosis, plasma cell leukemia, Waldenstrom macroglobulinemia or myelodysplastic syndrome * Received chemotherapy, biologics, or small molecule therapy within 21 days or 5 half-lives, whichever is shorter * Use of any non-approved or investigational agent ≤ 4 weeks prior to the first dose of study drug. * Received last prior anti-CD38 monoclonal antibody treatment within 28 days before first planned dose of the study drug * Current Grade \> 1 toxicity, with the exception of Grade 2 peripheral neuropathy, alopecia, or toxicities from prior anti-tumor therapy that are considered irreversible * Large-field radiotherapy within 28 days prior to Day 1 (radiation to a single site as concurrent therapy is allowed) * Prior autologous stem cell transplant within 180 days prior to Day 1 * Prior allogeneic stem cell transplant
Study Info
Organization
IGM Biosciences, Inc.
Primary Outcome
To evaluate the safety and tolerability of IGM-2644 in participants with multiple myeloma, including estimation of the maximum tolerated dose (MTD) or maximum administered dose (MAD)
Interventions
Locations Recruiting
City of Hope
United States, California, Duarte
Colorado Blood Cancer Institute
United States, Colorado, Denver
Memorial Sloan Kettering Cancer Center
United States, New York, New York
Tennessee Oncology (SCRI)
United States, Tennessee, Nashville
Fred Hutchinson Cancer Research Center
United States, Washington, Seattle
Interested in joining this trial?
Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.
![newsletter icon](https://static.healthtree.org/icons/newsletter-icon.png)
Get the latest thought leadership on your Multiple Myeloma delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.
Thanks to our HealthTree Community for Multiple Myeloma Sponsors:
![Johnson and Johnson](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FJohnson%20&%20Johnson%20Logo_64b18f59-85c9-4c20-a5ff-3842e69d8066.jpg?alt=media)
![Sanofi](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FSanofi%20updated%202023_d25a8d12-4f09-410c-9eb1-1e725b0b7c3e.jpg?alt=media)
![Pfizer](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FPfizer%20Logo%202024_50ae4587-5fdc-48e2-9a52-21651c643494.png?alt=media)
![Genentech](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/admin%2Fpublic%2Fshared%2FGenentech_Logo-700x182_e3c64168-dcf4-4540-9e9d-26500b26920a.png?alt=media)
![Regeneron](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FRegeneron_dec43aa4-fe53-4d5a-9b7f-4170101b47f9.webp?alt=media)
![Adaptive](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FAdaptive%20Logo%204.2023_e0d11d37-8b31-4c88-a0fc-4d07efc9b16b.png?alt=media)